Nanoparticles: A novel pulmonary drug delivery system for tuberculosis

Journal of Pharmaceutical Sciences and Research

Volumn 4, Issue 8, 2012, Pages 1901-1906

  Jawahar, N ^a   Reddy, Gowtham ^a  

^a JSS COLLEGE OF PHARMACY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID PLUS RIFAMPICIN; NANOPARTICLE; POLYMERIC NANOPARTICLE; PROTEIN NANOPARTICLE; SOLID LIPID NANOPARTICLE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; BIOCOMPATIBILITY; CRYSTALLIZATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; EVAPORATION; FREEZE DRYING; HUMAN; INHALATION; LUNG ALVEOLUS EPITHELIUM; MEDICAL NEBULIZER; METERED DOSE INHALER; NANOEMULSION; NANOENCAPSULATION; POWDER INHALER; PRECIPITATION; PULMONARY DRUG DELIVERY SYSTEM; SPRAY DRYING; SUPERCRITICAL FLUID EXTRACTION; TUBERCULOSIS;

EID: 84865069431     PISSN: 09751459     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Iseman MD. Tuberculosis. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007: chap 345.
2. Fitzgerald DW, Sterling TR, Haas DW. Mycobacterium tuberculosis. In: Mandell GL, Bennett JE, Dolan R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Orlando, FL: Saunders Elsevier; 2009: chap 250.)
3. Bakker-Woudenberg, I. A. J. M. Delivery of antimicrobials to Infected tissue macrophages. Adv. Drug Deliv. Rev. 1995, 17, 5-20.
4. Walker, C. B. Selected antimicrobial agents: mechanisms of action, Side effects and drug interactions. Periodontol 2000 1996, 10, 12-28.
5. Davis, M. E.; Chen, Z. G.; Shin, D. M. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat Rev Drug Discovery 2008, 7, 771-82.
6. Wagner, V.; Dullaart, A.; Bock, A.-K.; Zweck, A. The emerging Nanomedicine landscape. Nat. Biotechnol. 2006, 24, 1211-7.
7. Farokhzad, O. C.; Langer, R. Nanomedicine: developing smarter Therapeutic and diagnostic modalities. Adv. Drug Deliv. Rev. 2006, 58, 1456-9.
8. Lian, T.; Ho, R. J. Trends and developments in liposome drug Delivery systems. J. Pharm. Sci. 2001, 90, 667-80.
9. Vemuri, S.; Rhodes, C. T. Preparation and characterization of Liposomes as therapeutic delivery systems: a review. Pharma. Acta Helvetiae 1995, 70, 95-111.
10. Johnson, S. M.; Bangham, A. D.; Hill, M. W.; Korn, E. D. Single Bilayer liposomes. Biochim. Biophys. Acta 1971, 233, 820-6.
11. Olson, F.; Hunt, C. A.; Szoka, F. C.; Vail, W. J.; Papahadjopoulos, D. Preparation of liposomes of defined size distribution by extrusionThrough polycarbonate membranes. Biochim. Biophys. Acta 1979, 557, 9-23.
12. Adjei, A., Sundberg, D., Miller, J., and Chun, A. (1992). Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans, Pharm Res 9, 244-249.
13. Pelkonen, O., and Raunio, H. (1997). Expression and localization of CYP3A4 and CYP3A5 in human lung, Am J Respir Cell Mol Biol 16, 242-249.
14. Artursson, P. (1990). Epithelial transport of drugs in cell culture: I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells, J Pharm Sci 79, 476-482.
15. Audi, S. H., Dawson, C. A., Linehan, J. H., Krenz, G. S., Ahlf, S. B., and Roerig, D. L. (1998). Pulmonary disposition of lipophilic amine compounds in the isolated perfused rabbit lung, J Appl Physiol 84, 516-530.
16. Audi, S. H., Roerig, D. L., Ahlf, S. B., Lin, W., and Dawson, C. A. (1999). Pulmonary inflammation alters the lung disposition of lipophilic amine indicators, J Appl Physiol 87, 1831-1842.
17. Bagrij, T., Hladky, S. B., Stewart, S., Scheper, R. J., and Barrand, M. A. (1998). Studies of multidrug transport proteins in cells derived from human lung samples, Int J Clin Pharmacol Ther 36, 80-81.
18. Bassett, D. J. P., and Roth, R. A. (1992). The isolated perfused lung preparation. In: In vitro methods of toxicology, Watson, R. R., ed. (Boca Raton, Florida, CRC Press), pp. 143-155.
19. Ben-Jebria, A., Eskew, M. L., and Edwards, D. A. (2000). Inhalation systems for pulmonary aerosol drug delivery systems in rodents using large porous particles, Aerosol Sci Technol 32, 421-433.
20. Berg, M. M., Kim, K. J., Lubman, R. L., and Crandall, E. D. (1989). Hydrophilic solutetransport across rat alveolar epithelium, J Appl Physiol 66, 2320-7.
21. Bhat, P. G., Flanagan, D. R., and Donavan, M. D. (1995). The limiting role of mucus in drug absorption: drug permeation through mucus solution, Int J Pharm 126, 179-187.
22. Bodin, N.-O., Borg, K. O., Johansson, R., Ramsay, C.-H., and Skånberg, I. (1975). Tissue distribution of metoprolol-(3H) in the mouse and the rat, Acta Pharmacol Toxicol 36, 116-124.
23. Abu-Dahab R, Schäfer UF, Lehr C-M. 2001. Lectin-functionalized liposomes for pulmonary drug delivery: effect of nebulization on stability and bioadhesion. Eur J Pharm Sci, 14:37-46.
24. Adjei LA, Gupta PK. 1997. Inhalation delivery of therapeutic peptides and proteins. In Lenfant C, ed. Lung biology in health and disease. New York: Marcel Dekker, Inc. p 1913.
25. Arppe J, Vidgren M, Waldrep JC. 1998. Pulmonary pharmacokinetics of cyclosporin a liposomes. Int J Pharm, 161:205-14.
26. Benameur H, Latour N, Schandene L, et al. 1995. Liposome-incorporated dexamethasone palmitate inhibits in-vitro lymphocyte response to mitogen. J Pharm Pharmacol, 47:812-17.
27. Bennett JV, de Castro JF, Valdespino-Gomez JL, et al. 2002. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccine: randomized trials in Mexican school children. Bulletin of the World Health Organisation, 80:806-12.